Novartis Pluvicto FDA approval doubles mHSPC patient pool
Novartis receives FDA approval for Pluvicto in mHSPC, doubling the patient pool. Q2 revenue hit $651 million, up 43%. Five US manufacturing sites support rapid delivery.
*this image is generated using AI for illustrative purposes only.
The US Food and Drug Administration (FDA) approved Novartis AG’s Pluvicto (lutetium Lu 177 vipivotide tetraxetan) on July 31, 2026, for use in combination with an androgen receptor pathway inhibitor (ARPI) for patients with metastatic hormone-sensitive prostate cancer (mHSPC). This regulatory milestone nearly doubles the eligible patient population by expanding the drug’s indication beyond metastatic castration-resistant prostate cancer (mCRPC), introducing a precision treatment option at an earlier stage of the disease journey. The approval is grounded in Phase III PSMAddition trial data, which showed a 33% risk reduction in progression or death in updated analysis.
The expansion addresses a significant unmet need in oncology. Approximately 186,000 men are diagnosed with mHSPC globally each year. Despite advancements, about one-third of patients do not achieve undetectable PSA levels with standard ARPI-ADT therapy, and half progress to castration-resistant disease within 20 months. The PSMA biomarker is present in more than 80% of prostate cancer patients, making it a viable target for early intervention. Michael Morris, MD, Prostate Cancer Section Head at Memorial Sloan Kettering Cancer Center, stated that having a radioligand therapy available at this stage meaningfully expands options for physicians.
Clinical Efficacy and Safety
The PSMAddition trial evaluated Pluvicto combined with standard of care (SoC) against SoC alone. At primary analysis, the combination reduced the risk of progression or death by 28% (HR 0.72; 95% CI: 0.58–0.90). In a subsequent updated analysis, the risk reduction improved to 33% (HR 0.67; 95% CI: 0.55–0.82), with a positive overall survival trend favoring the Pluvicto arm (HR=0.80; 95% CI: 0.63–1.01).
| Metric | Primary Analysis | Updated Analysis |
|---|---|---|
| Risk Reduction (Progression/Death) | 28% | 33% |
| Hazard Ratio (Progression/Death) | 0.72 | 0.67 |
| Overall Survival Trend HR | — | 0.80 |
The safety profile in the mHSPC setting was consistent with previous trials. Grade ≥3 adverse events were reported in 50.7% of patients receiving Pluvicto plus SoC compared to 43.0% in the SoC-alone group. Common all-grade adverse events included dry mouth, fatigue, nausea, hot flushes, and anemia.
Commercial Impact and Manufacturing
Novartis reported a 43% revenue increase for Pluvicto in the second quarter, reaching $651 million. To support the expanded indication, the company has operationalized five radioligand therapy manufacturing sites in the US, with additional facilities under construction. This infrastructure allows delivery to US treatment sites within five days. Victor Bultó, President of Novartis US, noted that the approval signals a shift toward targeted, early intervention in prostate cancer care.
In other developments, the FDA granted traditional approval in July for Novartis’ oral medication Fabhalta (iptacopan) to slow kidney function decline in adult patients with primary immunoglobulin A nephropathy. Novartis shares were down 1.74% at $153.43 at the time of publication.
What the Numbers Show
The expansion into mHSPC significantly alters the commercial landscape for Novartis’ oncology portfolio. By addressing a population where half progress to castration-resistant disease within 20 months, Pluvicto is positioned as a foundational pillar of early-stage metastatic care. The 43% revenue growth in Q2 suggests strong initial adoption, while the dedicated US manufacturing footprint reduces logistical barriers that have historically limited radioligand therapy uptake.
Historical Stock Returns for Novartis
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.42% | -1.27% | -1.76% | +59.64% | +59.64% | +86.84% |
How will the expanded indication for Pluvicto impact the standard of care guidelines for metastatic hormone-sensitive prostate cancer, and will it displace current ARPI monotherapies?
What are the projected long-term cost implications for healthcare systems given the shift toward earlier, more expensive radioligand therapy interventions?
How might Novartis' competitors respond to this approval, and will we see accelerated development of competing PSMA-targeted therapies or alternative biomarker strategies?
20
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
